MediciNova, Inc. (MNOV) 10-Year Financial Performance & Capital Metrics

MNOV • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersAlzheimer's & Neurodegenerative

AboutMediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.Show more

Revenue $0 -100.0%
EBITDA -$13M -28.1%
Net Income -$11M -28.9%
EPS (Diluted) -0.23 -35.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -19.24% -48.8%
ROIC -79.44% -242.4%
Debt/Equity 0.00 +6.6%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 1.5x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-16.67%

EPS CAGR

10Y-

5Y-

3Y-

TTM-15.57%

ROCE

10Y Avg-22.34%

5Y Avg-17.46%

3Y Avg-18.49%

Latest-21.87%

Peer Comparison

Alzheimer's & Neurodegenerative

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
ANVSAnnovis Bio, Inc.	84.81M	3.20	-0.00			-189.15%
CLNNClene Inc.	60.19M	5.11	-0.90	-47.71%	-142.5%	-17.38%
ABOSAcumen Pharmaceuticals, Inc.	112.67M	1.86	-1.09			-143.12%	0.16
BHVNBiohaven Ltd.	1.58B	11.92	-1.28			-198.83%	0.09
IKTInhibikase Therapeutics, Inc.	200.09M	1.65	-1.42	-100%		-65.37%	0.00
ALECAlector, Inc.	198.66M	1.82	-1.48	3.6%	-156.03%	-186.68%	0.34
CGTXCognition Therapeutics, Inc.	121.82M	1.38	-1.62			-76.61%	0.04
ATHEAlterity Therapeutics Limited	60M	3.31	-2.90	35.32%	-330.63%	-73.75%	0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	4.04M	0	1M	0
Revenue Growth %	-	-	-	-	-	-	-	-1%	-	-1%
Cost of Goods Sold+	26.7K	14.13K	28.1K	25.88K	23.94K	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-26.7K	-14.13K	-28.1K	-25.88K	-23.94K	0	4.04M	0	1M	0
Gross Margin %	-	-	-	-	-	-	1%	-	1%	-
Gross Profit Growth %	-	0.47%	-0.99%	0.08%	0.07%	1%	-	-1%	-	-1%
Operating Expenses+	8.82M	10.88M	13.03M	15.59M	14.03M	14.18M	14.25M	14.63M	10.9M	12.68M
OpEx % of Revenue	-	-	-	-	-	-	3.53%	-	10.9%	-
Selling, General & Admin	5.81M	7.36M	8.8M	9.96M	7.95M	6.69M	5.72M	5.48M	5.24M	5.48M
SG&A % of Revenue	-	-	-	-	-	-	1.42%	-	5.24%	-
Research & Development	3.02M	3.52M	4.22M	5.63M	6.08M	7.49M	8.1M	9.14M	5.66M	7.2M
R&D % of Revenue	-	-	-	-	-	-	2.01%	-	5.66%	-
Other Operating Expenses	-14.82K	20.06K	120.2K	-22.89K	-46.16K	-357	438K	388	-400	-413
Operating Income+	-8.82M	-10.88M	-13.03M	-15.59M	-14.03M	-14.18M	-10.22M	-14.63M	-9.9M	-12.68M
Operating Margin %	-	-	-	-	-	-	-2.53%	-	-9.9%	-
Operating Income Growth %	0.04%	-0.23%	-0.2%	-0.2%	0.1%	-0.01%	0.28%	-0.43%	0.32%	-0.28%
EBITDA+	-8.8M	-10.87M	-13M	-15.56M	-14.01M	-14.16M	-10.19M	-14.61M	-9.88M	-12.65M
EBITDA Margin %	-	-	-	-	-	-	-2.52%	-	-9.88%	-
EBITDA Growth %	0.04%	-0.24%	-0.2%	-0.2%	0.1%	-0.01%	0.28%	-0.43%	0.32%	-0.28%
D&A (Non-Cash Add-back)	26.7K	14.13K	28.1K	25.88K	23.94K	21.34K	26.15K	17.71K	20.3K	21.08K
EBIT	-8.84M	-10.86M	-12.91M	-15.59M	-14.03M	-14.18M	-10.22M	-14.63M	-9.9M	-12.68M
Net Interest Income+	0	0	0	0	1.15M	361.18K	143.63K	809.67K	1.83M	1.67M
Interest Income	0	0	0	939.91K	1.15M	361.18K	143.63K	809.67K	1.83M	1.67M
Interest Expense	514	454	298	0	0	0	0	0	0	0
Other Income/Expense	-15.33K	19.61K	119.91K	917.01K	1.1M	322.78K	84.13K	562.39K	1.33M	1.63M
Pretax Income+	-8.84M	-10.86M	-12.91M	-14.67M	-12.93M	-13.86M	-10.13M	-14.07M	-8.57M	-11.04M
Pretax Margin %	-	-	-	-	-	-	-2.51%	-	-8.57%	-
Income Tax+	7.36K	3.75K	-1.74M	5.28K	12.66K	-1.65K	2.57K	2.82K	3.05K	5.54K
Effective Tax Rate %	1%	1%	0.86%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-8.85M	-10.87M	-11.16M	-14.68M	-12.94M	-13.85M	-10.13M	-14.07M	-8.57M	-11.05M
Net Margin %	-	-	-	-	-	-	-2.51%	-	-8.57%	-
Net Income Growth %	0.04%	-0.23%	-0.03%	-0.31%	0.12%	-0.07%	0.27%	-0.39%	0.39%	-0.29%
Net Income (Continuing)	-8.85M	-10.87M	-11.16M	-14.68M	-12.94M	-13.85M	-10.13M	-14.07M	-8.57M	-11.05M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.33	-0.33	-0.32	-0.36	-0.30	-0.31	-0.21	-0.29	-0.17	-0.23
EPS Growth %	0.13%	0%	0.03%	-0.13%	0.17%	-0.03%	0.32%	-0.38%	0.41%	-0.35%
EPS (Basic)	-0.33	-0.33	-0.32	-0.36	-0.30	-0.31	-0.21	-0.29	-0.17	-0.23
Diluted Shares Outstanding	26.58M	32.99M	35.14M	41.12M	43.16M	44.41M	48.6M	49.05M	49.05M	49.05M
Basic Shares Outstanding	26.58M	32.99M	35.14M	41.12M	43.16M	44.41M	48.6M	49.05M	49.05M	49.05M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	22.73M	24.7M	28.33M	62.76M	64.3M	60.72M	72.01M	58.99M	51.17M	41.07M
Cash & Short-Term Investments	22.08M	24.12M	27.99M	62.31M	63.79M	60.04M	71.43M	58.49M	51M	40.36M
Cash Only	22.08M	24.12M	27.99M	62.31M	63.79M	60.04M	71.43M	18.51M	51M	40.36M
Short-Term Investments	0	0	0	0	0	0	0	39.98M	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	511.92K	0	0	0	174.94K	714.54K
Total Non-Current Assets+	15.18M	15.11M	15.09M	14.46M	14.9M	14.7M	15.4M	15.17M	15.1M	14.8M
Property, Plant & Equipment	20.43K	90.72K	62.89K	53.13K	40.55K	226.56K	881.78K	674.76K	621.21K	382.41K
Fixed Asset Turnover	-	-	-	-	-	-	4.58x	-	1.61x	-
Goodwill	9.6M	9.6M	9.6M	9.6M	9.6M	9.6M	9.6M	9.6M	9.6M	9.6M
Intangible Assets	4.8M	4.8M	4.8M	4.8M	4.8M	4.8M	4.8M	4.8M	4.8M	4.8M
Long-Term Investments	650.47K	618.33K	616.66K	0	0	0	0	0	0	0
Other Non-Current Assets	108.98K	5.42B	10.96K	10.96K	459.81K	75.38K	115.49K	92.79K	74.15K	19K
Total Assets+	37.91M	39.81M	43.42M	77.22M	79.21M	75.42M	87.41M	74.15M	66.27M	55.88M
Asset Turnover	-	-	-	-	-	-	0.05x	-	0.02x	-
Asset Growth %	0.39%	0.05%	0.09%	0.78%	0.03%	-0.05%	0.16%	-0.15%	-0.11%	-0.16%
Total Current Liabilities+	1.49M	1.63M	2.88M	2.19M	2.23M	2.19M	2.83M	3.19M	3.28M	2.96M
Accounts Payable	170.79K	367.27K	1.52M	616.75K	451.33K	616.63K	402.74K	424.65K	1M	1.1M
Days Payables Outstanding	2.33K	9.49K	19.75K	8.7K	6.88K	-	-	-	-	-
Short-Term Debt	0	0	0	0	216.77K	0	0	0	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	0	0	0	0	0	0
Other Current Liabilities	0	0	0	191.93K	791.65K	924.3K	547.27K	184.1K	988.76K	912.78K
Current Ratio	15.25x	15.16x	9.83x	28.63x	28.86x	27.67x	25.42x	18.51x	15.61x	13.88x
Quick Ratio	15.25x	15.16x	9.83x	28.63x	28.86x	27.67x	25.42x	18.51x	15.61x	13.88x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	3.66M	3.65M	1.9M	1.92M	2.08M	1.9M	896.47K	725.41K	612.45K	413.25K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	182.58K	0	694.67K	523.62K	0	0
Deferred Tax Liabilities	1.96M	1.96M	201.79K	201.79K	201.79K	201.79K	0	0	201.79K	201.79K
Other Non-Current Liabilities	0	967	0	27.21K	3.78K	2.71K	201.79K	201.79K	410.66K	211.46K
Total Liabilities	5.15M	5.28M	4.78M	4.12M	4.31M	4.09M	3.73M	3.91M	3.89M	3.37M
Total Debt+	12.68M	967K	0	27.21M	399.35K	186.03K	826.64K	681.12K	215.93K	193.77K
Net Debt	-9.4M	-23.15M	-27.99M	-35.1M	-63.39M	-59.85M	-70.6M	-17.82M	-50.78M	-40.17M
Debt / Equity	0.39x	0.03x	-	0.37x	0.01x	0.00x	0.01x	0.01x	0.00x	0.00x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-17164.18x	-23968.80x	-43715.08x	-	-	-	-	-	-	-
Total Equity+	32.75M	34.53M	38.64M	73.11M	74.89M	71.33M	83.68M	70.24M	62.38M	52.5M
Equity Growth %	0.49%	0.05%	0.12%	0.89%	0.02%	-0.05%	0.17%	-0.16%	-0.11%	-0.16%
Book Value per Share	1.23	1.05	1.10	1.78	1.74	1.61	1.72	1.43	1.27	1.07
Total Shareholders' Equity	32.75M	34.53M	38.64M	73.11M	74.89M	71.33M	83.68M	70.24M	62.38M	52.5M
Common Stock	29.96K	34.52K	36.45K	42.08K	43.91K	45.02K	49.04K	49.05K	49.05K	49.05K
Retained Earnings	-319.43M	-330.29M	-341.46M	-356.13M	-369.07M	-382.93M	-393.06M	-407.13M	-415.7M	-426.75M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-102.77K	-96K	-94.62K	-93.15K	-92.68K	-88.22K	-98.88K	-115.28K	-118.09K	-135.15K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-7.15M	-6.55M	-6.92M	-9.11M	-9.12M	-10.83M	-9.38M	-12.91M	-7.43M	-10.64M
Operating CF Margin %	-	-	-	-	-	-	-2.32%	-	-7.43%	-
Operating CF Growth %	-9.76%	0.08%	-0.06%	-0.32%	-0%	-0.19%	0.13%	-0.38%	0.42%	-0.43%
Net Income	-8.85M	-10.87M	-11.16M	-14.68M	-12.94M	-13.85M	-10.13M	-14.07M	-8.57M	-11.05M
Depreciation & Amortization	26.7K	14.13K	28.1K	25.88K	23.94K	21.34K	26.15K	17.71K	20.3K	21.08K
Stock-Based Compensation	2.03M	3.97M	4.47M	6.33M	4.11M	3.18M	1.72M	642.52K	710.71K	1.19M
Deferred Taxes	0	-1.9K	-1.9M	0	0	0	0	0	0	0
Other Non-Cash Items	34.32K	32.14K	1.9M	-19.87K	0	210.21K	216.93K	163.19K	297.49K	173.32K
Working Capital Changes	-393.81K	302.87K	-265.51K	-775.35K	-319.92K	-379.57K	-1.21M	334.1K	111.99K	-979.56K
Change in Receivables	-284.54K	175.5K	242.06K	-111.68K	-514.02K	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	-181.93M	127.37K	1.25M	-663.67K	194.1K	-4.77K	-1.03M	329.01K	19.24K	-312.35K
Cash from Investing+	-2.32K	-84.48K	-84.48M	626.32K	-11.27K	-36.49K	-28.73K	-40.01M	39.91M	-697
Capital Expenditures	-2.32K	-84.48K	0	-10.2K	-11.27K	-36.49K	-28.73K	-5.01K	-21.3K	-895
CapEx % of Revenue	-	-	-	-	-	-	0.01%	-	0.02%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-2.32M	-84.48M	-84.48M	636.52K	0	0	0	-5.01M	0	198
Cash from Financing+	17.56M	8.67M	10.8M	42.81M	10.62M	7.11M	20.78M	7.92K	0	0
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	89.91K	87.73K	77.32K	51.01K	-261.05K	-192.13K	-112.26K	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-7.15M	-6.63M	-6.92M	-9.12M	-9.14M	-10.86M	-9.41M	-12.92M	-7.45M	-10.64M
FCF Margin %	-	-	-	-	-	-	-2.33%	-	-7.45%	-
FCF Growth %	-9.8%	0.07%	-0.04%	-0.32%	-0%	-0.19%	0.13%	-0.37%	0.42%	-0.43%
FCF per Share	-0.27	-0.20	-0.20	-0.22	-0.21	-0.24	-0.19	-0.26	-0.15	-0.22
FCF Conversion (FCF/Net Income)	0.81x	0.60x	0.62x	0.62x	0.71x	0.78x	0.93x	0.92x	0.87x	0.96x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	7.44K	6.04K	9.2K	6K	11.27K	1.49K	0	0	3.67K	5.04K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-32.3%	-32.3%	-30.51%	-26.26%	-17.49%	-18.95%	-13.08%	-18.28%	-12.93%	-19.24%
Return on Invested Capital (ROIC)	-25.23%	-46.99%	-88.69%	-48.05%	-42.51%	-92.56%	-62.42%	-33.51%	-23.2%	-79.44%
Gross Margin	-	-	-	-	-	-	100%	-	100%	-
Net Margin	-	-	-	-	-	-	-251%	-	-857.15%	-
Debt / Equity	0.39x	0.03x	-	0.37x	0.01x	0.00x	0.01x	0.01x	0.00x	0.00x
Interest Coverage	-17164.18x	-23968.80x	-43715.08x	-	-	-	-	-	-	-
FCF Conversion	0.81x	0.60x	0.62x	0.62x	0.71x	0.78x	0.93x	0.92x	0.87x	0.96x
Revenue Growth	-	-	-	-	-	-	-	-100%	-	-100%

Frequently Asked Questions

Growth & Financials

MediciNova, Inc. (MNOV) reported $0.3M in revenue for fiscal year 2024.

MediciNova, Inc. (MNOV) saw revenue decline by 100.0% over the past year.

MediciNova, Inc. (MNOV) reported a net loss of $12.0M for fiscal year 2024.

Dividend & Returns

MediciNova, Inc. (MNOV) has a return on equity (ROE) of -19.2%. Negative ROE indicates the company is unprofitable.

MediciNova, Inc. (MNOV) had negative free cash flow of $9.7M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

MediciNova, Inc. (MNOV) 10-Year Financial Performance & Capital Metrics

MNOV • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersAlzheimer's & Neurodegenerative

Revenue $0 -100.0%
EBITDA -$13M -28.1%
Net Income -$11M -28.9%
EPS (Diluted) -0.23 -35.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -19.24% -48.8%
ROIC -79.44% -242.4%
Debt/Equity 0.00 +6.6%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 1.5x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-16.67%

EPS CAGR

10Y-

5Y-

3Y-

TTM-15.57%

ROCE

10Y Avg-22.34%

5Y Avg-17.46%

3Y Avg-18.49%

Latest-21.87%

Peer Comparison

Alzheimer's & Neurodegenerative

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
ANVSAnnovis Bio, Inc.	84.81M	3.20	-0.00			-189.15%
CLNNClene Inc.	60.19M	5.11	-0.90	-47.71%	-142.5%	-17.38%
ABOSAcumen Pharmaceuticals, Inc.	112.67M	1.86	-1.09			-143.12%	0.16
BHVNBiohaven Ltd.	1.58B	11.92	-1.28			-198.83%	0.09
IKTInhibikase Therapeutics, Inc.	200.09M	1.65	-1.42	-100%		-65.37%	0.00
ALECAlector, Inc.	198.66M	1.82	-1.48	3.6%	-156.03%	-186.68%	0.34
CGTXCognition Therapeutics, Inc.	121.82M	1.38	-1.62			-76.61%	0.04
ATHEAlterity Therapeutics Limited	60M	3.31	-2.90	35.32%	-330.63%	-73.75%	0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	4.04M	0	1M	0
Revenue Growth %	-	-	-	-	-	-	-	-1%	-	-1%
Cost of Goods Sold+	26.7K	14.13K	28.1K	25.88K	23.94K	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-26.7K	-14.13K	-28.1K	-25.88K	-23.94K	0	4.04M	0	1M	0
Gross Margin %	-	-	-	-	-	-	1%	-	1%	-
Gross Profit Growth %	-	0.47%	-0.99%	0.08%	0.07%	1%	-	-1%	-	-1%
Operating Expenses+	8.82M	10.88M	13.03M	15.59M	14.03M	14.18M	14.25M	14.63M	10.9M	12.68M
OpEx % of Revenue	-	-	-	-	-	-	3.53%	-	10.9%	-
Selling, General & Admin	5.81M	7.36M	8.8M	9.96M	7.95M	6.69M	5.72M	5.48M	5.24M	5.48M
SG&A % of Revenue	-	-	-	-	-	-	1.42%	-	5.24%	-
Research & Development	3.02M	3.52M	4.22M	5.63M	6.08M	7.49M	8.1M	9.14M	5.66M	7.2M
R&D % of Revenue	-	-	-	-	-	-	2.01%	-	5.66%	-
Other Operating Expenses	-14.82K	20.06K	120.2K	-22.89K	-46.16K	-357	438K	388	-400	-413
Operating Income+	-8.82M	-10.88M	-13.03M	-15.59M	-14.03M	-14.18M	-10.22M	-14.63M	-9.9M	-12.68M
Operating Margin %	-	-	-	-	-	-	-2.53%	-	-9.9%	-
Operating Income Growth %	0.04%	-0.23%	-0.2%	-0.2%	0.1%	-0.01%	0.28%	-0.43%	0.32%	-0.28%
EBITDA+	-8.8M	-10.87M	-13M	-15.56M	-14.01M	-14.16M	-10.19M	-14.61M	-9.88M	-12.65M
EBITDA Margin %	-	-	-	-	-	-	-2.52%	-	-9.88%	-
EBITDA Growth %	0.04%	-0.24%	-0.2%	-0.2%	0.1%	-0.01%	0.28%	-0.43%	0.32%	-0.28%
D&A (Non-Cash Add-back)	26.7K	14.13K	28.1K	25.88K	23.94K	21.34K	26.15K	17.71K	20.3K	21.08K
EBIT	-8.84M	-10.86M	-12.91M	-15.59M	-14.03M	-14.18M	-10.22M	-14.63M	-9.9M	-12.68M
Net Interest Income+	0	0	0	0	1.15M	361.18K	143.63K	809.67K	1.83M	1.67M
Interest Income	0	0	0	939.91K	1.15M	361.18K	143.63K	809.67K	1.83M	1.67M
Interest Expense	514	454	298	0	0	0	0	0	0	0
Other Income/Expense	-15.33K	19.61K	119.91K	917.01K	1.1M	322.78K	84.13K	562.39K	1.33M	1.63M
Pretax Income+	-8.84M	-10.86M	-12.91M	-14.67M	-12.93M	-13.86M	-10.13M	-14.07M	-8.57M	-11.04M
Pretax Margin %	-	-	-	-	-	-	-2.51%	-	-8.57%	-
Income Tax+	7.36K	3.75K	-1.74M	5.28K	12.66K	-1.65K	2.57K	2.82K	3.05K	5.54K
Effective Tax Rate %	1%	1%	0.86%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-8.85M	-10.87M	-11.16M	-14.68M	-12.94M	-13.85M	-10.13M	-14.07M	-8.57M	-11.05M
Net Margin %	-	-	-	-	-	-	-2.51%	-	-8.57%	-
Net Income Growth %	0.04%	-0.23%	-0.03%	-0.31%	0.12%	-0.07%	0.27%	-0.39%	0.39%	-0.29%
Net Income (Continuing)	-8.85M	-10.87M	-11.16M	-14.68M	-12.94M	-13.85M	-10.13M	-14.07M	-8.57M	-11.05M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.33	-0.33	-0.32	-0.36	-0.30	-0.31	-0.21	-0.29	-0.17	-0.23
EPS Growth %	0.13%	0%	0.03%	-0.13%	0.17%	-0.03%	0.32%	-0.38%	0.41%	-0.35%
EPS (Basic)	-0.33	-0.33	-0.32	-0.36	-0.30	-0.31	-0.21	-0.29	-0.17	-0.23
Diluted Shares Outstanding	26.58M	32.99M	35.14M	41.12M	43.16M	44.41M	48.6M	49.05M	49.05M	49.05M
Basic Shares Outstanding	26.58M	32.99M	35.14M	41.12M	43.16M	44.41M	48.6M	49.05M	49.05M	49.05M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	22.73M	24.7M	28.33M	62.76M	64.3M	60.72M	72.01M	58.99M	51.17M	41.07M
Cash & Short-Term Investments	22.08M	24.12M	27.99M	62.31M	63.79M	60.04M	71.43M	58.49M	51M	40.36M
Cash Only	22.08M	24.12M	27.99M	62.31M	63.79M	60.04M	71.43M	18.51M	51M	40.36M
Short-Term Investments	0	0	0	0	0	0	0	39.98M	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	511.92K	0	0	0	174.94K	714.54K
Total Non-Current Assets+	15.18M	15.11M	15.09M	14.46M	14.9M	14.7M	15.4M	15.17M	15.1M	14.8M
Property, Plant & Equipment	20.43K	90.72K	62.89K	53.13K	40.55K	226.56K	881.78K	674.76K	621.21K	382.41K
Fixed Asset Turnover	-	-	-	-	-	-	4.58x	-	1.61x	-
Goodwill	9.6M	9.6M	9.6M	9.6M	9.6M	9.6M	9.6M	9.6M	9.6M	9.6M
Intangible Assets	4.8M	4.8M	4.8M	4.8M	4.8M	4.8M	4.8M	4.8M	4.8M	4.8M
Long-Term Investments	650.47K	618.33K	616.66K	0	0	0	0	0	0	0
Other Non-Current Assets	108.98K	5.42B	10.96K	10.96K	459.81K	75.38K	115.49K	92.79K	74.15K	19K
Total Assets+	37.91M	39.81M	43.42M	77.22M	79.21M	75.42M	87.41M	74.15M	66.27M	55.88M
Asset Turnover	-	-	-	-	-	-	0.05x	-	0.02x	-
Asset Growth %	0.39%	0.05%	0.09%	0.78%	0.03%	-0.05%	0.16%	-0.15%	-0.11%	-0.16%
Total Current Liabilities+	1.49M	1.63M	2.88M	2.19M	2.23M	2.19M	2.83M	3.19M	3.28M	2.96M
Accounts Payable	170.79K	367.27K	1.52M	616.75K	451.33K	616.63K	402.74K	424.65K	1M	1.1M
Days Payables Outstanding	2.33K	9.49K	19.75K	8.7K	6.88K	-	-	-	-	-
Short-Term Debt	0	0	0	0	216.77K	0	0	0	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	0	0	0	0	0	0
Other Current Liabilities	0	0	0	191.93K	791.65K	924.3K	547.27K	184.1K	988.76K	912.78K
Current Ratio	15.25x	15.16x	9.83x	28.63x	28.86x	27.67x	25.42x	18.51x	15.61x	13.88x
Quick Ratio	15.25x	15.16x	9.83x	28.63x	28.86x	27.67x	25.42x	18.51x	15.61x	13.88x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	3.66M	3.65M	1.9M	1.92M	2.08M	1.9M	896.47K	725.41K	612.45K	413.25K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	182.58K	0	694.67K	523.62K	0	0
Deferred Tax Liabilities	1.96M	1.96M	201.79K	201.79K	201.79K	201.79K	0	0	201.79K	201.79K
Other Non-Current Liabilities	0	967	0	27.21K	3.78K	2.71K	201.79K	201.79K	410.66K	211.46K
Total Liabilities	5.15M	5.28M	4.78M	4.12M	4.31M	4.09M	3.73M	3.91M	3.89M	3.37M
Total Debt+	12.68M	967K	0	27.21M	399.35K	186.03K	826.64K	681.12K	215.93K	193.77K
Net Debt	-9.4M	-23.15M	-27.99M	-35.1M	-63.39M	-59.85M	-70.6M	-17.82M	-50.78M	-40.17M
Debt / Equity	0.39x	0.03x	-	0.37x	0.01x	0.00x	0.01x	0.01x	0.00x	0.00x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-17164.18x	-23968.80x	-43715.08x	-	-	-	-	-	-	-
Total Equity+	32.75M	34.53M	38.64M	73.11M	74.89M	71.33M	83.68M	70.24M	62.38M	52.5M
Equity Growth %	0.49%	0.05%	0.12%	0.89%	0.02%	-0.05%	0.17%	-0.16%	-0.11%	-0.16%
Book Value per Share	1.23	1.05	1.10	1.78	1.74	1.61	1.72	1.43	1.27	1.07
Total Shareholders' Equity	32.75M	34.53M	38.64M	73.11M	74.89M	71.33M	83.68M	70.24M	62.38M	52.5M
Common Stock	29.96K	34.52K	36.45K	42.08K	43.91K	45.02K	49.04K	49.05K	49.05K	49.05K
Retained Earnings	-319.43M	-330.29M	-341.46M	-356.13M	-369.07M	-382.93M	-393.06M	-407.13M	-415.7M	-426.75M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-102.77K	-96K	-94.62K	-93.15K	-92.68K	-88.22K	-98.88K	-115.28K	-118.09K	-135.15K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-7.15M	-6.55M	-6.92M	-9.11M	-9.12M	-10.83M	-9.38M	-12.91M	-7.43M	-10.64M
Operating CF Margin %	-	-	-	-	-	-	-2.32%	-	-7.43%	-
Operating CF Growth %	-9.76%	0.08%	-0.06%	-0.32%	-0%	-0.19%	0.13%	-0.38%	0.42%	-0.43%
Net Income	-8.85M	-10.87M	-11.16M	-14.68M	-12.94M	-13.85M	-10.13M	-14.07M	-8.57M	-11.05M
Depreciation & Amortization	26.7K	14.13K	28.1K	25.88K	23.94K	21.34K	26.15K	17.71K	20.3K	21.08K
Stock-Based Compensation	2.03M	3.97M	4.47M	6.33M	4.11M	3.18M	1.72M	642.52K	710.71K	1.19M
Deferred Taxes	0	-1.9K	-1.9M	0	0	0	0	0	0	0
Other Non-Cash Items	34.32K	32.14K	1.9M	-19.87K	0	210.21K	216.93K	163.19K	297.49K	173.32K
Working Capital Changes	-393.81K	302.87K	-265.51K	-775.35K	-319.92K	-379.57K	-1.21M	334.1K	111.99K	-979.56K
Change in Receivables	-284.54K	175.5K	242.06K	-111.68K	-514.02K	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	-181.93M	127.37K	1.25M	-663.67K	194.1K	-4.77K	-1.03M	329.01K	19.24K	-312.35K
Cash from Investing+	-2.32K	-84.48K	-84.48M	626.32K	-11.27K	-36.49K	-28.73K	-40.01M	39.91M	-697
Capital Expenditures	-2.32K	-84.48K	0	-10.2K	-11.27K	-36.49K	-28.73K	-5.01K	-21.3K	-895
CapEx % of Revenue	-	-	-	-	-	-	0.01%	-	0.02%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-2.32M	-84.48M	-84.48M	636.52K	0	0	0	-5.01M	0	198
Cash from Financing+	17.56M	8.67M	10.8M	42.81M	10.62M	7.11M	20.78M	7.92K	0	0
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	89.91K	87.73K	77.32K	51.01K	-261.05K	-192.13K	-112.26K	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-7.15M	-6.63M	-6.92M	-9.12M	-9.14M	-10.86M	-9.41M	-12.92M	-7.45M	-10.64M
FCF Margin %	-	-	-	-	-	-	-2.33%	-	-7.45%	-
FCF Growth %	-9.8%	0.07%	-0.04%	-0.32%	-0%	-0.19%	0.13%	-0.37%	0.42%	-0.43%
FCF per Share	-0.27	-0.20	-0.20	-0.22	-0.21	-0.24	-0.19	-0.26	-0.15	-0.22
FCF Conversion (FCF/Net Income)	0.81x	0.60x	0.62x	0.62x	0.71x	0.78x	0.93x	0.92x	0.87x	0.96x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	7.44K	6.04K	9.2K	6K	11.27K	1.49K	0	0	3.67K	5.04K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-32.3%	-32.3%	-30.51%	-26.26%	-17.49%	-18.95%	-13.08%	-18.28%	-12.93%	-19.24%
Return on Invested Capital (ROIC)	-25.23%	-46.99%	-88.69%	-48.05%	-42.51%	-92.56%	-62.42%	-33.51%	-23.2%	-79.44%
Gross Margin	-	-	-	-	-	-	100%	-	100%	-
Net Margin	-	-	-	-	-	-	-251%	-	-857.15%	-
Debt / Equity	0.39x	0.03x	-	0.37x	0.01x	0.00x	0.01x	0.01x	0.00x	0.00x
Interest Coverage	-17164.18x	-23968.80x	-43715.08x	-	-	-	-	-	-	-
FCF Conversion	0.81x	0.60x	0.62x	0.62x	0.71x	0.78x	0.93x	0.92x	0.87x	0.96x
Revenue Growth	-	-	-	-	-	-	-	-100%	-	-100%

Frequently Asked Questions

Growth & Financials

MediciNova, Inc. (MNOV) reported $0.3M in revenue for fiscal year 2024.

MediciNova, Inc. (MNOV) saw revenue decline by 100.0% over the past year.

MediciNova, Inc. (MNOV) reported a net loss of $12.0M for fiscal year 2024.

Dividend & Returns

MediciNova, Inc. (MNOV) has a return on equity (ROE) of -19.2%. Negative ROE indicates the company is unprofitable.

MediciNova, Inc. (MNOV) had negative free cash flow of $9.7M in fiscal year 2024, likely due to heavy capital investments.